BRAF and metastatic malignant neoplasm in the lymph nodes: Previous studies have verified that patients with PTC frequently carry the BRAF mutation, with prevalence rates reaching 73.4% (Hiroyuki et al., 2003; Maaitah et al., 2019; Xing et al., 2015), while aggressive behaviors, such as capsule invasion, vessel invasion and lymph node metastasis are linked to the BRAF mutation (Conzo et al., 2012; Gambardella et al., 2019; Marotta et al., 2016).